Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin® 24 FE Tablets

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 09/14/2017.
  • Additional Information
    • Alternate Title:
      PA-Mylan-launches
    • Subject Terms:
      England; Pennsylvania
    • Abstract:
      HERTFORDSHIRE, England and PITTSBURGH, Sept. 14, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, 1 mg/20 mcg, which is indicated for use by women to prevent pregnancy (1). Mylan's subsidiary, Mylan Laboratories Limited, received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is a generic version of Allergan's Minastrin® 24 FE Tablets. [ABSTRACT FROM PUBLISHER]